Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 76


Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.

Oertel WH, Hallström Y, Saletu-Zyhlarz GM, Hopp M, Bosse B, Trenkwalder C; RELOXYN Study Group.

CNS Drugs. 2016 Aug;30(8):749-60. doi: 10.1007/s40263-016-0372-1.


Early diagnosis and successful management of oral mucormycosis in a hematopoietic stem cell transplant recipient: case report and literature review.

Epstein JB, Kupferman SB, Zabner R, Rejali A, Hopp ML, Lill M, Tzachanis D.

Support Care Cancer. 2016 Aug;24(8):3343-6. doi: 10.1007/s00520-016-3170-x. Epub 2016 Mar 14.


Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.

Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M; PANDA study group.

Lancet Neurol. 2015 Dec;14(12):1161-70. doi: 10.1016/S1474-4422(15)00243-4. Epub 2015 Oct 19.


PDE3A mutations cause autosomal dominant hypertension with brachydactyly.

Maass PG, Aydin A, Luft FC, Schächterle C, Weise A, Stricker S, Lindschau C, Vaegler M, Qadri F, Toka HR, Schulz H, Krawitz PM, Parkhomchuk D, Hecht J, Hollfinger I, Wefeld-Neuenfeld Y, Bartels-Klein E, Mühl A, Kann M, Schuster H, Chitayat D, Bialer MG, Wienker TF, Ott J, Rittscher K, Liehr T, Jordan J, Plessis G, Tank J, Mai K, Naraghi R, Hodge R, Hopp M, Hattenbach LO, Busjahn A, Rauch A, Vandeput F, Gong M, Rüschendorf F, Hübner N, Haller H, Mundlos S, Bilginturan N, Movsesian MA, Klussmann E, Toka O, Bähring S.

Nat Genet. 2015 Jun;47(6):647-53. doi: 10.1038/ng.3302. Epub 2015 May 11.


The Socioeconomic Costs of the Undertreatment of Pain.

Hopp M, Bosse B, Dunlop W.

Value Health. 2014 Nov;17(7):A785. doi: 10.1016/j.jval.2014.08.400. Epub 2014 Oct 26. No abstract available.


Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials.

Blagden M, Hafer J, Duerr H, Hopp M, Bosse B.

Neurogastroenterol Motil. 2014 Dec;26(12):1792-801. doi: 10.1111/nmo.12463. Epub 2014 Oct 23.


Hair for brain trade-off, a metabolic bypass for encephalization.

Dror Y, Hopp M.

Springerplus. 2014 Sep 27;3:562. doi: 10.1186/2193-1801-3-562. eCollection 2014.


Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain.

Ahmedzai SH, Leppert W, Janecki M, Pakosz A, Lomax M, Duerr H, Hopp M.

Support Care Cancer. 2015 Mar;23(3):823-30. doi: 10.1007/s00520-014-2435-5. Epub 2014 Sep 14.


Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.

Trenkwalder C, Beneš H, Grote L, García-Borreguero D, Högl B, Hopp M, Bosse B, Oksche A, Reimer K, Winkelmann J, Allen RP, Kohnen R; RELOXYN Study Group.

Lancet Neurol. 2013 Dec;12(12):1141-50. doi: 10.1016/S1474-4422(13)70239-4. Epub 2013 Oct 18. Erratum in: Lancet Neurol. 2013 Dec;12(12):1133.


Low absolute bioavailability of oral naloxone in healthy subjects.

Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, Bell D.

Int J Clin Pharmacol Ther. 2012 May;50(5):360-7.


Cardiac disease in methylmalonic acidemia.

Prada CE, Al Jasmi F, Kirk EP, Hopp M, Jones O, Leslie ND, Burrow TA.

J Pediatr. 2011 Nov;159(5):862-4. doi: 10.1016/j.jpeds.2011.06.005. Epub 2011 Jul 23.


Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers.

Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, Palaniappan K, Church A, Limb M, Connor A.

Expert Opin Investig Drugs. 2011 Apr;20(4):427-39. doi: 10.1517/13543784.2011.563236.


Observational, nonintervention, multicenter study for validation of the Bowel Function Index for constipation in European countries.

Rentz AM, van Hanswijck de Jonge P, Leyendecker P, Hopp M.

Curr Med Res Opin. 2011 Jan;27(1):35-44. doi: 10.1185/03007995.2010.535270. Epub 2010 Nov 18.


Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.

Sandner-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejcko J, Meissner W, Sevcik P, Hakl M, Hrib R, Uhl R, Dürr H, Reimer K.

Int J Clin Pract. 2010 May;64(6):763-74. doi: 10.1111/j.1742-1241.2010.02360.x. Epub 2010 Mar 29.


Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management.

Holzer P, Ahmedzai SH, Niederle N, Leyendecker P, Hopp M, Bosse B, Spohr I, Reimer K.

J Opioid Manag. 2009 May-Jun;5(3):145-51. Review.


Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.

Löwenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, Bond S, Kremers W, Nichols T, Krain B, Reimer K.

Expert Opin Pharmacother. 2009 Mar;10(4):531-43. doi: 10.1517/14656560902796798 .


Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.

Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P, Grothe B, Uhl R, Reimer K.

Clin Ther. 2008 Nov;30(11):2051-68. doi: 10.1016/j.clinthera.2008.11.008.


Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.

Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, Troy Ferrarons J, Bosse B, Krain B, Nichols T, Kremers W, Reimer K.

Curr Med Res Opin. 2008 Dec;24(12):3503-12. doi: 10.1185/03007990802584454 .

Items per page

Supplemental Content

Support Center